TendoNova
TendoNova Corporation is an Atlanta-based medical device company that develops and manufactures the Ocelot, an FDA-cleared, handheld, battery-powered device for office-based ultrasound-guided tenotomy to treat chronic tendinopathies, sold to orthopedic and sports medicine physicians via direct sales and channel partners.
- Company typePrivate
- Founded2017
- HeadquartersSuwanee, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What TendoNova does
TendoNova Corporation is a medical technology company founded in 2017 and headquartered in Atlanta, Georgia, that develops and manufactures the Ocelot, a handheld, battery-powered, FDA 510(k)-cleared micro-invasive device for office-based, ultrasound-guided percutaneous tenotomy to treat chronic tendinopathies. The system consists of a reusable drive unit, a charging station, and a sterile single-use disposable unit housing a rapidly oscillating stainless-steel Franseen cutter that mechanically fragments and debrides diseased tendon tissue, with an integrated cannula port that can be left in place for targeted delivery of biologic agents such as platelet-rich plasma after the procedure. Two issued U.S. patents (US 10,631,888 in April 2020 and US 11,357,530 in June 2022) protect the device, and manufacturing is performed in-house in Atlanta. The technology is positioned against ultrasonic tenotomy modalities such as Tenex, with the company's marketing materials specifically calling out the risk of burns from ultrasonic energy as a point of differentiation.
TendoNova sells to orthopedic surgeons, sports medicine physicians, physiatrists, and interventional MSK radiologists practicing in office-based and ambulatory surgical center settings, targeting indications including lateral/medial epicondylitis, plantar fasciitis, rotator cuff impingement, patellar tendinopathy, and Achilles, hamstring, gluteal, and quadriceps tendinopathy. Its revenue model is razor-and-blade: a one-time capital sale of the reusable drive unit and charging station to the practice, layered with recurring per-procedure sales of the sterile disposable cutting-tool assembly. Distribution combines a U.S. direct field-sales team led by a National Sales Director with channel partnerships, most notably AcCELLerated Biologics (signed March 2023), and an online "Find a Doctor" directory on tendonova.com that drives patient demand-side pull. Pricing is quote-based and not publicly disclosed, with clinicians directed to a 15-minute online demo and direct sales contact. A digital health companion (tablet plus mobile/device app) that captures device telemetry for procedure feedback is in development.
Commercial validation includes named accounts at Emory Sports Medicine, Mayo Clinic (Rochester), Dovetail Orthopedics, and Optim Orthopedics. Clinical study data referenced on the company site reports that 87% of patients treated for refractory tendinopathy reported positive results, with peer-reviewed support from Sharma & Thomas (2010), Strauser-Curtis et al. (2022), and Barnes et al. (2015). The company is backed by a 2017 founding team, NFL Players Inc. (2020), the Georgia Research Alliance (multiple grants), and a 2024 Preferred capital raise led by VentureSouth with CampbellKlein as co-investor. The company has 1-10 employees and no public revenue disclosure.
TendoNova firmographics
Firmographics- Name
- TendoNova
- Legal name
- TendoNova Corporation
- Website
- https://tendonova.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- TendoNova Corporation is an Atlanta-based medical device company that develops and manufactures the Ocelot, an FDA-cleared, handheld, battery-powered device for office-based ultrasound-guided tenotomy to treat chronic tendinopathies, sold to orthopedic and sports medicine physicians via direct sales and channel partners.
- Ownership category
- akta.pro rank
TendoNova industry classification
Industry- Product category
- Orthopedic Medical Devices
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Pain Management (Spine & Musculoskeletal) (HLAKALAM)
- akta.pro secondary industries
- Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM), Hand & Upper Extremity (HLAKALAF), Orthopedic Trauma & Extremities Fixation (Plates/Screws/Nails/External Fixation) (HLAHAEAB)
Keywords
Where TendoNova is headquartered
LocationHeadquarters
- HQ city
- Suwanee
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
TendoNova business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Capital hardware sales (reusable drive unit + charging station): One-time sale of the reusable handheld Ocelot drive unit and its charging station to physician practices, clinics, and ambulatory surgical centers. Represents the upfront capital expenditure by the customer.
- Recurring sterile disposable unit sales: Recurring revenue from single-use sterile disposable units that house the cutting tool assembly; each procedure consumes one disposable, producing a razor/blade-style annuity on top of the capital install base.
- Channel / distribution sales through partners: Indirect sales via distribution and channel partners (e.g., AcCELLerated Biologics) that carry the Ocelot alongside biologic adjacencies to expand reach to additional physician accounts.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Quote-based pricing for clinicians |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels8 records
TendoNova product offering
Product offeringCore offering
TendoNova develops and manufactures the Ocelot (also referenced as Ocelot Nano and Ocelot TSD 1000), an FDA 510(k)-cleared, handheld, battery-powered micro-invasive medical device for percutaneous tenotomy and mechanical fragmentation/debridement of soft tissue. The Ocelot system consists of a reusable drive unit, a charging station, and a sterile single-use disposable unit housing a rapidly oscillating stainless-steel Franseen cutter, and is sold to orthopedic and sports medicine physicians for in-office treatment of chronic tendinopathies. Recurring revenue is generated through single-use disposable units consumed per procedure, on top of the upfront capital sale of the drive unit.
Product overview
TendoNova offers a single core medical-device product — the Ocelot system (also referred to as Ocelot Nano and Ocelot TSD 1000) — supported by an optional digital-health add-on (a tablet companion with a mobile/device application) rather than a multi-module software platform. The Ocelot itself is an FDA-cleared, micro-invasive, handheld, battery-powered device used for percutaneous tenotomy and mechanical fragmentation/debridement of soft tissue in chronic tendinopathies, and is sold alongside a reusable drive unit, charging station, and disposable cutting-tool assembly. TendoNova's broader product roadmap is a series of instrumented micro-invasive tools designed to combine mechanical tenotomy with targeted delivery of biologic agents (e.g., platelet-rich plasma) and procedural feedback to clinicians.
Differentiator
Problem solved
Functional benefit
Brands
- Ocelot®: TendoNova's flagship line of FDA-cleared microinvasive, portable, handheld, battery-powered medical devices for percutaneous tenotomy and soft tissue fragmentation/debridement.
- Ocelot® Nano
- Ocelot™ TSD 1000
Products and services
- Ocelot (Ocelot Nano / Ocelot TSD 1000) micro-invasive tenotomy system FDA-cleared, portable, handheld, battery-powered medical device for micro-invasive mechanical fragmentation and debridement of soft tissue via a rapidly oscillating stainless-steel Franseen cutter, used under ultrasound guidance for percutaneous tenotomy in chronic tendinopathies; sold to orthopedic, sports medicine, and office-based physicians.
- Ocelot sterile single-use disposable cutting-tool assembly Single-use sterile disposable unit housing the cutting-tool assembly for the Ocelot system; one is consumed per procedure, enabling the razor/blade recurring revenue model and ensuring sterility.
Quantifiable outcome
- 87% of patients treated for refractory tendinopathy reported positive results in a clinical study
- +4 more outcomes
Companies that use TendoNova
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles2 records
TendoNova technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
TendoNova partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AcCELLerated BiologicsflagshipAgreement signed March 8, 2023 to significantly expand the sales network for TendoNova's lead product, the Ocelot. AcCELLerated Biologics brings a decade of experience training and equipping physicians with biologic tools; the partnership gives the Ocelot access to those biologic customers and enables pairing of Ocelot tenotomy with biologic products. AcCELLerated Biologics CEO Steve Whyte commented publicly on the partnership.
Scale indicators10 records
Recent moves6 records
Expansion highlights5 records
TendoNova competitors and assessment
Company assessmentDirect peers
- Tenex Health: Tenex Health manufactures the established ultrasonic percutaneous tenotomy system that TendoNova explicitly positions the Ocelot against. It is the most direct competitor in office-based tenotomy for chronic tendinopathy and shares the same clinical call point and procedure workflow.
- HydroCision (TenJet): HydroCision's TenJet system performs minimally invasive tenotomy using a high-velocity saline jet. It competes head-to-head with the Ocelot in ultrasound-guided percutaneous tenotomy for tendinopathy and targets the same orthopedic and sports medicine physicians.
Broad incumbents
- Arthrex: Arthrex is a private global leader in sports medicine and orthopedic surgical devices, including arthroscopic and percutaneous instruments. While it does not sell a direct tenotomy-only device, it covers the same surgeon call points and competes broadly for procedure share.
- Smith+Nephew: Smith+Nephew's Sports Medicine & ENT franchise sells arthroscopic, tendon repair, and minimally invasive orthopedic instruments. It is a broad incumbent whose portfolio overlaps with the procedural category TendoNova targets.
- Stryker: Stryker's orthopedic and surgical equipment portfolio (and prior acquisition of HyperBranch Medical Technology, where TendoNova director Jeffrey Clark was CEO) competes in the same MSK procedure space and represents a likely strategic acquirer profile for early-stage orthopedic device companies.
- CONMED: CONMED provides general surgery, orthopedic, and sports medicine devices including arthroscopic and electrosurgical instruments. It serves the same office-based and ASC clinician segment that the Ocelot targets for tenotomy procedures.
- Integra LifeSciences: Integra LifeSciences offers orthopedic, sports medicine, and regenerative tissue technologies, including minimally invasive soft-tissue instruments. It is a broad incumbent with overlapping sports-medicine procedural adjacencies.
Emerging players
- MiMedx: MiMedx sells regenerative tissue grafts and orthobiologics used in sports medicine and orthopedic surgery, complementing office-based tenotomy procedures. It is comparable via the biologics-plus-tenotomy workflow TendoNova promotes through its PRP cannula port.
- Anika Therapeutics: Anika Therapeutics develops hyaluronic-acid-based and regenerative products for orthopedic and sports medicine applications. It targets the same MSK call points and overlaps thematically with TendoNova's tendon-pain focus.
- Isto Biologics: Isto Biologics provides autologous bone-marrow concentrate and orthobiologic products used in sports medicine and orthopedic procedures. It is an emerging player in the same clinical workflow that the Ocelot serves, often co-administered with tenotomy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
TendoNova social profiles
Digital presenceTendoNova compliance and trust
Trust signalCompliance5 records
TendoNova financial estimates
Financial estimateRevenue estimate
Valuation estimate
TendoNova leadership team
Management profileNumber of profiles
Profiles13 records
TendoNova funding detail
Funding detailFunding overview
Funding rounds10 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TendoNova M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TendoNova
What does TendoNova do?
TendoNova develops and manufactures the Ocelot (also referenced as Ocelot Nano and Ocelot TSD 1000), an FDA 510(k)-cleared, handheld, battery-powered micro-invasive medical device for percutaneous tenotomy and mechanical fragmentation/debridement of soft tissue. The Ocelot system consists of a reusable drive unit, a charging station, and a sterile single-use disposable unit housing a rapidly oscillating stainless-steel Franseen cutter, and is sold to orthopedic and sports medicine physicians for in-office treatment of chronic tendinopathies. Recurring revenue is generated through single-use disposable units consumed per procedure, on top of the upfront capital sale of the drive unit.
Is TendoNova a public or private company?
TendoNova is a private company. It is classified as venture growth investor backed and is currently operating.
When was TendoNova founded?
TendoNova was founded in 2017. It employs 1 to 10 people.
Where is TendoNova based?
TendoNova is headquartered in Suwanee, United States, in the North America region.
How does TendoNova make money?
Three revenue lines are on record. Capital hardware sales (reusable drive unit + charging station) is the primary driver. The others are recurring sterile disposable unit sales and channel / distribution sales through partners.
Who are TendoNova's main competitors?
Direct peers on record are Tenex Health and HydroCision (TenJet). Broad incumbents are Arthrex, Smith+Nephew, Stryker, CONMED and Integra LifeSciences. Emerging players are MiMedx, Anika Therapeutics and Isto Biologics.
Does TendoNova have an API?
No public API is recorded for TendoNova.
What industry is TendoNova in?
TendoNova's product category is Orthopedic Medical Devices. Its primary akta.pro industry code is HLAKALAM, Pain Management (Spine & Musculoskeletal), with a secondary code of HLAHADAM, Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits). Its NAICS code is 339113 and its SIC code is 3841.